These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24186922)

  • 1. Initial experience with rivaroxaban in mechanical valve prosthesis in an animal model.
    Aramendi JI; Mestres CA
    Eur J Cardiothorac Surg; 2014 May; 45(5):920-1. PubMed ID: 24186922
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.
    Greiten LE; McKellar SH; Rysavy J; Schaff HV
    Eur J Cardiothorac Surg; 2014 May; 45(5):914-9. PubMed ID: 24306948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".
    Turpie AG
    J Clin Pharmacol; 2011 Jul; 51(7):1122-3. PubMed ID: 21666147
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban for treatment of HIT: a riveting first experience.
    Linkins LA; Warkentin TE
    Thromb Res; 2015 Jan; 135(1):1-2. PubMed ID: 25466840
    [No Abstract]   [Full Text] [Related]  

  • 5. New oral anticoagulants show promise.
    Hampton T
    JAMA; 2006 Feb; 295(7):743-4. PubMed ID: 16478891
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible Rivaroxaban Failure during the Postpartum Period: An Alternative Viewpoint.
    Bond AM; Bartle B; Rudd KM; McFee Winans AR
    Pharmacotherapy; 2016 Apr; 36(4):e26-7. PubMed ID: 26952042
    [No Abstract]   [Full Text] [Related]  

  • 7. Periprocedural management of rivaroxaban-treated patients.
    Imberti D; Ambrosoli A; Cimminiello C; Compagnone C; Fanelli A; Tripodi A; Ottani F
    Expert Opin Pharmacother; 2015 Apr; 16(5):685-91. PubMed ID: 25690076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical Prosthesis.
    Durães AR; Bitar YSL; Lima MLG; Santos CC; Schonhofen IS; Filho JAL; Roever L
    Am J Cardiol; 2018 Sep; 122(6):1047-1050. PubMed ID: 30098707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
    Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].
    Greco C
    Monaldi Arch Chest Dis; 2014 Mar; 82(1):16-9. PubMed ID: 25481935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for treatment of venous thromboembolism in older adults.
    Mitchell AP; Conway SE
    Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome.
    Bachmeyer C; Elalamy I
    Clin Exp Dermatol; 2014 Oct; 39(7):840-1. PubMed ID: 25186062
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
    Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
    Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of the rivaroxaban for heparin-induced thrombocytopenia study.
    Linkins LA; Warkentin TE; Pai M; Shivakumar S; Manji RA; Wells PS; Crowther MA
    J Thromb Thrombolysis; 2014 Nov; 38(4):485-92. PubMed ID: 24549975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary to the article: "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
    Undas A
    Kardiol Pol; 2016; 74(5):504-5. PubMed ID: 27197012
    [No Abstract]   [Full Text] [Related]  

  • 18. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report.
    Abouchakra L; Khabbaz Z; Abouassi S; Badaoui G
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):e19-20. PubMed ID: 26055438
    [No Abstract]   [Full Text] [Related]  

  • 19. A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses.
    McKellar SH; Thompson JL; Schaff HV
    J Surg Res; 2007 Jul; 141(1):1-6. PubMed ID: 17512549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
    Lasek-Bal A; Urbanek T; Puz P; Piekarski M
    Kardiol Pol; 2016; 74(5):506. PubMed ID: 27197013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.